AIM Immunotech

AIM ImmunoTech Inc., founded in the United States, is a biopharmaceutical company dedicated to the research and development of innovative therapeutics for cancer and immune-deficiency disorders. The company's core mission is to advance immunology to create a better future for patients suffering from debilitating and life-threatening conditions. AIM ImmunoTech's flagship product, Ampligen®, is an immuno-modulator with broad-spectrum activity, currently being evaluated in clinical studies for various disease areas, including oncology, immune disorders, and viral diseases.

Notable figures associated with AIM ImmunoTech include its experienced leadership team and scientific advisors who bring extensive expertise in immunology and pharmaceutical development. The company has attracted significant investment from both private and institutional investors, enabling it to progress its clinical trials and research initiatives. AIM ImmunoTech's key achievements include successful preclinical and clinical evaluations of Ampligen®, positioning it as a promising therapeutic candidate. The company's impact lies in its potential to offer new treatment options for patients with limited alternatives, thereby contributing to advancements in medical science and patient care.